Anavex Life Sciences News and Activities

Anavex Life Sciences is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Anavex Life Sciences is a company listed under the stock ticker AVXL (US).

View the org chart displaying its 21 main executives

Most searched biographies at Anavex Life Sciences

• Jiong Ma, Director
• Steffen Thomas, Director
• Peter Donhauser, Director

Popular executive movements at Anavex Life Sciences

• Terrie Kellmeyer, who was Senior Vice President of Clinical Development, is promoted to Interim Chief Executive Officer  (posted on May 6 2026).
• Axel Paeger has joined the company as Director  (posted on February 24 2026).
• Wolfgang Liedtke has joined the company as Senior Vice President, Global Head of Neurology  (posted on January 8 2026).

Create your alert
to follow the executive moves at Anavex Life Sciences.

Anavex Life Sciences has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Anavex Life Sciences

• Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification | Anavex Life Sciences
• Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer | Anavex Life Sciences
• Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease | Anavex Life Sciences
• Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference | Anavex Life Sciences
• Anavex Life Sciences Provides Comprehensive Regulatory Update | Anavex Life Sciences
• Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease | Anav
• Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease | Anavex Life Sciences
• Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference | Anavex Life Sciences
• New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease | Anavex Life Sciences
• Anavex Life Sciences to Present at the Citizens Life Sciences Conference | Anavex Life Sciences
• View more press releases Close

Social media about Anavex Life Sciences

• Anavex Life Sciences on Wikipedia, Google News & Yahoo Finance
• Anavex Life Sciences on LinkedIn, X (Twitter) & YouTube